JP2016504992A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016504992A5 JP2016504992A5 JP2015548639A JP2015548639A JP2016504992A5 JP 2016504992 A5 JP2016504992 A5 JP 2016504992A5 JP 2015548639 A JP2015548639 A JP 2015548639A JP 2015548639 A JP2015548639 A JP 2015548639A JP 2016504992 A5 JP2016504992 A5 JP 2016504992A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- group
- ethanol
- methylamino
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 208000010877 cognitive disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- GIGVAWWBRRBBAJ-UHFFFAOYSA-N 2-[4-[3-(methylamino)-1-phenylpropoxy]phenyl]ethanol Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(CCO)C=C1 GIGVAWWBRRBBAJ-UHFFFAOYSA-N 0.000 claims 3
- 208000012239 Developmental disease Diseases 0.000 claims 3
- 208000012902 Nervous system disease Diseases 0.000 claims 3
- 230000003542 behavioural effect Effects 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 208000020016 psychiatric disease Diseases 0.000 claims 3
- 102100021257 Beta-secretase 1 Human genes 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- GBWFSDNIWQRAFG-UHFFFAOYSA-N 1-[2-[4-(2-hydroxyethyl)phenoxy]ethyl]pyrrolidin-2-one Chemical compound C1=CC(CCO)=CC=C1OCCN1C(=O)CCC1 GBWFSDNIWQRAFG-UHFFFAOYSA-N 0.000 claims 1
- DSCFFEYYQKSRSV-UHFFFAOYSA-N 1L-O1-methyl-muco-inositol Natural products COC1C(O)C(O)C(O)C(O)C1O DSCFFEYYQKSRSV-UHFFFAOYSA-N 0.000 claims 1
- -1 2- [4- [3- (methylamino) -1-phenylpropoxy] phenyl] ethanol (R) -lipoic acid salt Chemical class 0.000 claims 1
- UYYDGUWIYGERMB-UHFFFAOYSA-N 2-[4-(morpholin-2-ylmethoxy)phenyl]ethanol;hydrochloride Chemical compound Cl.C1=CC(CCO)=CC=C1OCC1OCCNC1 UYYDGUWIYGERMB-UHFFFAOYSA-N 0.000 claims 1
- YQSGMMPWDSHWDJ-GMUIIQOCSA-N 2-[4-[(1r)-3-(methylamino)-1-phenylpropoxy]phenyl]ethanol;hydrochloride Chemical compound Cl.O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(CCO)C=C1 YQSGMMPWDSHWDJ-GMUIIQOCSA-N 0.000 claims 1
- OAEMFLGMZNYRKM-OAHLLOKOSA-N 2-[4-[(1r)-3-(methylamino)-1-thiophen-2-ylpropoxy]phenyl]ethanol Chemical compound O([C@H](CCNC)C=1SC=CC=1)C1=CC=C(CCO)C=C1 OAEMFLGMZNYRKM-OAHLLOKOSA-N 0.000 claims 1
- YQSGMMPWDSHWDJ-FERBBOLQSA-N 2-[4-[(1s)-3-(methylamino)-1-phenylpropoxy]phenyl]ethanol;hydrochloride Chemical compound Cl.O([C@@H](CCNC)C=1C=CC=CC=1)C1=CC=C(CCO)C=C1 YQSGMMPWDSHWDJ-FERBBOLQSA-N 0.000 claims 1
- OAEMFLGMZNYRKM-HNNXBMFYSA-N 2-[4-[(1s)-3-(methylamino)-1-thiophen-2-ylpropoxy]phenyl]ethanol Chemical compound O([C@@H](CCNC)C=1SC=CC=1)C1=CC=C(CCO)C=C1 OAEMFLGMZNYRKM-HNNXBMFYSA-N 0.000 claims 1
- YQSGMMPWDSHWDJ-UHFFFAOYSA-N 2-[4-[3-(methylamino)-1-phenylpropoxy]phenyl]ethanol;hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CCNC)OC1=CC=C(CCO)C=C1 YQSGMMPWDSHWDJ-UHFFFAOYSA-N 0.000 claims 1
- CKAFHCHOEVHXAE-PXNSSMCTSA-N 2-[4-[[(3s,4r)-4-(4-fluorophenyl)piperidin-3-yl]methoxy]phenyl]ethanol Chemical compound C1=CC(CCO)=CC=C1OC[C@H]1[C@H](C=2C=CC(F)=CC=2)CCNC1 CKAFHCHOEVHXAE-PXNSSMCTSA-N 0.000 claims 1
- BAGMPXLPHMULTJ-UHFFFAOYSA-N 2-[4-[morpholin-2-yl(phenyl)methoxy]phenyl]ethanol Chemical compound C1=CC(CCO)=CC=C1OC(C=1C=CC=CC=1)C1OCCNC1 BAGMPXLPHMULTJ-UHFFFAOYSA-N 0.000 claims 1
- JJZFWROHYSMCMU-UHFFFAOYSA-N 3-(benzenesulfonyl)-8-piperazin-1-ylquinoline Chemical compound C=1N=C2C(N3CCNCC3)=CC=CC2=CC=1S(=O)(=O)C1=CC=CC=C1 JJZFWROHYSMCMU-UHFFFAOYSA-N 0.000 claims 1
- MZRKHUUDDHJVHS-MOKVOYLWSA-N 3-ethyl-n-[(5s)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]-2-oxobenzimidazole-1-carboxamide Chemical compound C1C(N2C)CC[C@H]2CC1NC(=O)N1C2=CC=CC=C2N(CC)C1=O MZRKHUUDDHJVHS-MOKVOYLWSA-N 0.000 claims 1
- VCQZCDSEWSFTPO-SJORKVTESA-N 4-[(1s,2s)-2-(4-cyclobutylpiperazine-1-carbonyl)cyclopropyl]benzamide Chemical compound C1=CC(C(=O)N)=CC=C1[C@@H]1[C@@H](C(=O)N2CCN(CC2)C2CCC2)C1 VCQZCDSEWSFTPO-SJORKVTESA-N 0.000 claims 1
- KAKWRMDVZQPECF-UHFFFAOYSA-N 4-[4-[3-(methylamino)-1-phenylpropoxy]phenyl]butan-1-ol;hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CCNC)OC1=CC=C(CCCCO)C=C1 KAKWRMDVZQPECF-UHFFFAOYSA-N 0.000 claims 1
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000009575 Angelman syndrome Diseases 0.000 claims 1
- 208000036640 Asperger disease Diseases 0.000 claims 1
- 201000006062 Asperger syndrome Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 101710150192 Beta-secretase 1 Proteins 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- OFVNMCFEMDCZKP-PWKISDLSSA-N CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)CCOC3=C(C(=O)O[C@@H]3[C@H](CO)O)O Chemical compound CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)CCOC3=C(C(=O)O[C@@H]3[C@H](CO)O)O OFVNMCFEMDCZKP-PWKISDLSSA-N 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- VJXUJFAZXQOXMJ-UHFFFAOYSA-N D-1-O-Methyl-muco-inositol Natural products CC12C(OC)(C)OC(C)(C)C2CC(=O)C(C23OC2C(=O)O2)(C)C1CCC3(C)C2C=1C=COC=1 VJXUJFAZXQOXMJ-UHFFFAOYSA-N 0.000 claims 1
- DSCFFEYYQKSRSV-KLJZZCKASA-N D-pinitol Chemical compound CO[C@@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@H]1O DSCFFEYYQKSRSV-KLJZZCKASA-N 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 208000024412 Friedreich ataxia Diseases 0.000 claims 1
- 102000004300 GABA-A Receptors Human genes 0.000 claims 1
- 108090000839 GABA-A Receptors Proteins 0.000 claims 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims 1
- 229940125373 Gamma-Secretase Inhibitor Drugs 0.000 claims 1
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- ZRJBHWIHUMBLCN-SEQYCRGISA-N Huperzine A Natural products N1C(=O)C=CC2=C1C[C@H]1/C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-SEQYCRGISA-N 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 102000010909 Monoamine Oxidase Human genes 0.000 claims 1
- 108010062431 Monoamine oxidase Proteins 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims 1
- 208000006289 Rett Syndrome Diseases 0.000 claims 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims 1
- ZRJBHWIHUMBLCN-UHFFFAOYSA-N Shuangyiping Natural products N1C(=O)C=CC2=C1CC1C(=CC)C2(N)CC(C)=C1 ZRJBHWIHUMBLCN-UHFFFAOYSA-N 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims 1
- PBHFNBQPZCRWQP-AZUAARDMSA-N [(3aS,8bR)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-phenylcarbamate Chemical compound CN([C@H]1[C@](C2=C3)(C)CCN1C)C2=CC=C3OC(=O)NC1=CC=CC=C1 PBHFNBQPZCRWQP-AZUAARDMSA-N 0.000 claims 1
- WCLRTWSSCPEHJI-UHFFFAOYSA-N [4-[3-(methylamino)-1-phenylpropoxy]phenyl]methanol;hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CCNC)OC1=CC=C(CO)C=C1 WCLRTWSSCPEHJI-UHFFFAOYSA-N 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000001896 anti-amyloidogenic effect Effects 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 1
- UTMVACIBQLDZLP-UHFFFAOYSA-N crisdesalazine Chemical compound C1=C(O)C(C(=O)O)=CC(NCCC=2C=CC(=CC=2)C(F)(F)F)=C1 UTMVACIBQLDZLP-UHFFFAOYSA-N 0.000 claims 1
- 229960003530 donepezil Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940030275 epigallocatechin gallate Drugs 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- OPQRBXUBWHDHPQ-UHFFFAOYSA-N etazolate Chemical compound CCOC(=O)C1=CN=C2N(CC)N=CC2=C1NN=C(C)C OPQRBXUBWHDHPQ-UHFFFAOYSA-N 0.000 claims 1
- 229950009329 etazolate Drugs 0.000 claims 1
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 claims 1
- 229940114123 ferulate Drugs 0.000 claims 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 claims 1
- 229960003980 galantamine Drugs 0.000 claims 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims 1
- 239000003540 gamma secretase inhibitor Substances 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 claims 1
- 239000003395 histamine H3 receptor antagonist Substances 0.000 claims 1
- ZRJBHWIHUMBLCN-YQEJDHNASA-N huperzine A Chemical compound N1C(=O)C=CC2=C1C[C@H]1\C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-YQEJDHNASA-N 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 230000028252 learning or memory Effects 0.000 claims 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims 1
- 229960004640 memantine Drugs 0.000 claims 1
- 239000000359 muscarinic M1 receptor agonist Substances 0.000 claims 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- ZRJBHWIHUMBLCN-BMIGLBTASA-N rac-huperzine A Natural products N1C(=O)C=CC2=C1C[C@@H]1C(=CC)[C@@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-BMIGLBTASA-N 0.000 claims 1
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 claims 1
- 229960000245 rasagiline Drugs 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 229940016667 resveratrol Drugs 0.000 claims 1
- 235000021283 resveratrol Nutrition 0.000 claims 1
- 229960004136 rivastigmine Drugs 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 claims 1
- 229940102566 valproate Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12382527.5 | 2012-12-21 | ||
| EP12382527.5A EP2745876A1 (en) | 2012-12-21 | 2012-12-21 | Hydroxy aliphatic substituted phenyl aminoalkyl ether derivatives |
| PCT/EP2013/077731 WO2014096377A1 (en) | 2012-12-21 | 2013-12-20 | Hydroxy aliphatic substituted phenyl aminoalkyl ether derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016504992A JP2016504992A (ja) | 2016-02-18 |
| JP2016504992A5 true JP2016504992A5 (https=) | 2017-01-05 |
| JP6302929B2 JP6302929B2 (ja) | 2018-03-28 |
Family
ID=47559245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015548639A Active JP6302929B2 (ja) | 2012-12-21 | 2013-12-20 | ヒドロキシ脂肪族置換フェニルアミノアルキルエーテル誘導体 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9624158B2 (https=) |
| EP (2) | EP2745876A1 (https=) |
| JP (1) | JP6302929B2 (https=) |
| AU (1) | AU2013366502B2 (https=) |
| CA (1) | CA2895592C (https=) |
| DK (1) | DK2945702T3 (https=) |
| ES (1) | ES2621960T3 (https=) |
| HR (1) | HRP20170539T1 (https=) |
| HU (1) | HUE032461T2 (https=) |
| PT (1) | PT2945702T (https=) |
| WO (1) | WO2014096377A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2647377A1 (en) | 2012-04-06 | 2013-10-09 | Sanofi | Use of an h3 receptor antagonist for the treatment of alzheimer's disease |
| CN105764510A (zh) * | 2013-09-09 | 2016-07-13 | 赛诺菲 | H3受体拮抗剂与胆碱酶抑制剂组合用于阿尔茨海默氏病治疗中的用途 |
| CN106349211B (zh) * | 2016-08-26 | 2020-10-16 | 江苏恩华药业股份有限公司 | 2-甲基-3-芳氧基-3-杂芳基丙胺类化合物及应用 |
| KR101864085B1 (ko) * | 2017-09-22 | 2018-06-01 | 동아대학교 산학협력단 | 발프로산 유도체, 이의 제조방법 및 이를 포함하는 항경련제 |
| JP2020536941A (ja) * | 2017-10-16 | 2020-12-17 | エステベ ファーマシューティカルズ, ソシエダッド アノニマEsteve Pharmaceuticals, S.A. | 疼痛及び疼痛に関連する状態を治療するためのプロパンアミン誘導体 |
| TW202014191A (zh) | 2018-04-27 | 2020-04-16 | 日商鹽野義製藥股份有限公司 | 具有選擇性ｂａｃｅ１抑制活性的四氫哌喃并衍生物 |
| US12139476B2 (en) | 2018-08-17 | 2024-11-12 | Shanghai Leado Pharmatech Co. Ltd. | 3-aryloxyl-3-five-membered heteroaryl propylamine compound and use thereof |
| WO2020228789A1 (zh) | 2019-05-16 | 2020-11-19 | 上海璃道医药科技有限公司 | 3-芳氧基-3-五元杂芳基-丙胺类化合物及其晶型和用途 |
| JP7709202B2 (ja) * | 2019-06-28 | 2025-07-16 | ユニバーシティ オブ コペンハーゲン | 睡眠障害を伴うｃｎｓ障害の治療 |
| KR20250030127A (ko) * | 2023-08-24 | 2025-03-05 | 경희대학교 산학협력단 | 피니톨을 함유한 감각 운동 관문 장애 예방 또는 치료용 조성물 |
| EP4678628A1 (en) | 2024-07-10 | 2026-01-14 | Connecta Theapeutics, S.L. | Compounds and compositions for the treatment of nervous system disorders |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004532834A (ja) * | 2001-03-23 | 2004-10-28 | イーライ・リリー・アンド・カンパニー | ヒスタミンｈ３受容体アンタゴニストである非イミダゾール系アリールアルキルアミン化合物、その製造および治療的使用 |
| WO2003082259A1 (en) * | 2002-04-03 | 2003-10-09 | Puleva Biotech, S.A. | Natural phenolic products and derivatives thereof for protection against neurodegenerative diseases |
| BRPI0510453A (pt) | 2004-04-30 | 2007-10-30 | Warner Lambert Co | composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central |
| GB0409744D0 (en) | 2004-04-30 | 2004-06-09 | Pfizer Ltd | Novel compounds |
| SE526297C2 (sv) | 2004-07-27 | 2005-08-16 | Jan Norrman | Kopplingsstycke innefattande en ledare med flertal trådar vilka är fördelade kring en deformerbar kropps ytteromkrets |
| GB0505509D0 (en) * | 2005-03-17 | 2005-04-27 | Ic Innovations Ltd | Compounds |
| SI1813614T1 (sl) | 2006-01-25 | 2012-01-31 | Sanofi 174 | Citotoksična sredstva, ki obsegajo nove tomajmicinske derivate |
| CN100528832C (zh) * | 2007-02-08 | 2009-08-19 | 刘宏民 | 左旋盐酸倍他洛尔合成工艺 |
| US20120004310A1 (en) * | 2010-05-28 | 2012-01-05 | Longo Frank M | Non-peptide bdnf neurotrophin mimetics |
| EP2664616A1 (en) * | 2012-05-15 | 2013-11-20 | Vivalis | Hydantoin and thiohydantoin derivatives as antiviral drugs |
-
2012
- 2012-12-21 EP EP12382527.5A patent/EP2745876A1/en not_active Withdrawn
-
2013
- 2013-12-20 DK DK13811569.6T patent/DK2945702T3/en active
- 2013-12-20 EP EP13811569.6A patent/EP2945702B1/en active Active
- 2013-12-20 JP JP2015548639A patent/JP6302929B2/ja active Active
- 2013-12-20 CA CA2895592A patent/CA2895592C/en active Active
- 2013-12-20 WO PCT/EP2013/077731 patent/WO2014096377A1/en not_active Ceased
- 2013-12-20 ES ES13811569.6T patent/ES2621960T3/es active Active
- 2013-12-20 AU AU2013366502A patent/AU2013366502B2/en active Active
- 2013-12-20 PT PT138115696T patent/PT2945702T/pt unknown
- 2013-12-20 HU HUE13811569A patent/HUE032461T2/en unknown
- 2013-12-20 HR HRP20170539TT patent/HRP20170539T1/hr unknown
- 2013-12-20 US US14/654,661 patent/US9624158B2/en active Active
-
2017
- 2017-04-17 US US15/489,186 patent/US9980928B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016504992A5 (https=) | ||
| HRP20170539T1 (hr) | Hidroksialifatski supstituirani derivati fenilaminoalkil-etera | |
| RU2016131875A (ru) | Производные n-фениллактама, способные стимулировать нейрогенез, и их применение при лечении заболеваний нервной системы | |
| JP2015509535A5 (https=) | ||
| RU2017132673A (ru) | Производные собетирома | |
| JP2014051526A5 (https=) | ||
| JP2013523733A5 (https=) | ||
| JP2015501799A5 (https=) | ||
| JP2014526469A5 (https=) | ||
| JP2015509110A5 (https=) | ||
| JP2012530779A5 (https=) | ||
| JP2014505017A5 (https=) | ||
| JP2014062126A5 (https=) | ||
| RU2015112914A (ru) | Бензимидазолы в качестве активных агентов для центральной нервной системы | |
| RU97102362A (ru) | Нейрозащитные производные 3-(пиперидинил-1)-хроман-4,7-диола и 1-(4- гидроксифенил)-2-(пиперидинил-1)-алканола | |
| JP2019513755A5 (https=) | ||
| JP2012532125A5 (https=) | ||
| JP2013522368A5 (https=) | ||
| JP2013506674A5 (https=) | ||
| JP2017509694A5 (https=) | ||
| JP2016537338A5 (https=) | ||
| RU2016104890A (ru) | Производные 1,7-нафтиридина | |
| RU2011102523A (ru) | Новые производные тетраметил-замещенного пиперидина и их применение в качестве ингибиторов обратного захвата моноаминовых нейромедиаторов | |
| EA201692488A1 (ru) | Пептиды, выполняющие роль агонистов окситоцина | |
| RU2015148927A (ru) | Производные изохинолина, стимулирующие нейрогенез |